Avacta Group PLC - Wetherby, England-based pre-clinical stage biotechnology company - States it is not involved with the development of Medusa 19's Covid-19 antibody test. Issues clarification following information appearing on the Medusa 19 website regarding a SARS-CoV-2 antibody test on Friday, adding that performance figures appearing on Medusa 19' site relate to this antibody test and do not relate to Avacta's rapid SARS-CoV-2 antigen test.
Current stock price: 145.00 pence
Year-to-date change: up more than eight-fold from 17.25p
By Ife Taiwo; firstname.lastname@example.org
Copyright 2020 Alliance News Limited. All Rights Reserved.